Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Autor: Alice P. Chen, James H. Doroshow, John J. Wright, Rene Costello, Donald Bottaro, Andrea Regier Voth, Naoko Takebe, Elad Sharon, Howard Streicher, Richard Piekarz, Robert Meehan, Lamin Juwara, Jared C. Foster, Lawrence Rubinstein, Ashley Bruns, Jennifer Zlott, Khanh T. Do, Warren A. Chow, Kristen Ganjoo, James Hu, Shivaani Kummar, Geraldine O'Sullivan Coyne

Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18093bd7818563307195df58214a4506
https://doi.org/10.1158/1078-0432.22483926

Design of phase II oncology trials evaluating combinations of experimental agents

Autor: Elad Sharon, Jared C Foster

Publikováno v: JNCI: Journal of the National Cancer Institute.

We consider the design of phase II trials evaluating combinations of experimental therapies. In the modern era, many immunotherapy and targeted therapy regimens are being developed as combination regimens, including combinations consisting only of ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b35fa431dd65872ef9741dd1bea32f8b
https://doi.org/10.1093/jnci/djad052

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Autor: Jane Perlmutter, Victoria S. Blinder, Laleh Amiri-Kordestani, Jared C. Foster, Eileen Rakovitch, Eric P. Winer, Angelo DiLeo, Julia White, Anthony D. Elias, Ana F. Best, Lynn Pearson Butler, Sara M. Tolaney, Lawrence Baizer, Patricia A. Spears, Elena Schwartz, David Cameron, Elizabeth Garrett-Mayer, Neelima Denduluri, Elizabeth S. Frank, Larissa A. Korde, E. Shelley Hwang, Nadine Tung, Judith M Bliss

Publikováno v: M Tolaney, S, Garrett-Mayer, E, White, J, S. Blinder, V, C. Foster, J, Amiri Kordestani, L, Hwang, S, M. Bliss, J, Rakovitch, E, Perlmutter, J, A. Spears, P, Frank, E, M. Tung, N, D. Elias, A, Cameron, D A, Denduluri, N, F. Best, A, Di Leo, A, Baizer, L, Pearson Butler, L, Schwartz, E, P Winer, E & A. Korde, L 2021, ' Updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0 ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.20.03613
J Clin Oncol

PURPOSEThe Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial end points. Given the evolution of breast cancer clinical trials and improvem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462fd891363195e2418ad331df8718fa
https://doi.org/10.1200/jco.20.03613

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma

Autor: Mohamad Adham Salkeni, Anthony Paul Conley, James Lin Chen, Elizabeth J. Davis, Melissa Amber Burgess, Albiruni Ryan Abdul Razak, Nancy Moore, Katherine V. Ferry-Galow, Kristin K. Fino, King Leung Fung, Ralph E. Parchment, Jared C. Foster, Christina Rosenberger, Geraldine Helen O'Sullivan Coyne, Naoko Takebe, Elad Sharon, James H. Doroshow, Alice P. Chen

Publikováno v: Journal of Clinical Oncology. 40:11528-11528

11528 Background: Chondrosarcoma is one of the most common bone malignancies in adults, and the third most common in pediatric patients (pts). The most prevalent subtype, conventional chondrosarcoma, is a slow growing tumor that is historically known

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::604b5f9eac5d22a82039ab9516e3abd0
https://doi.org/10.1200/jco.2022.40.16_suppl.11528

Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

Autor: Kathryn Lurain, Richard F. Little, Howard Streicher, Ravie Kem, Jared C. Foster, Elad Sharon, Joshua E. Reuss, Diana Stern, Ramya Ramaswami, Helen X. Chen

Publikováno v: JAMA Network Open

Key Points Question Has inclusion of people living with HIV in anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) immunotherapy trials changed during ongoing Cancer Therapy Evaluation Program advocacy efforts by the Nati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5d3178c756d6e8739d3289f4292bdde
http://europepmc.org/articles/PMC7709086